Divalproex sodium for seizure control, bipolar mania, and migraine prevention

Divalproex sodium is an oral medication used primarily to treat various types of seizures, manage acute manic or mixed episodes of bipolar disorder, and prevent migraine headaches. It is available in multiple forms including delayed-release capsules and tablets, and extended-release tablets, allowing for flexible use in different patient populations and treatment settings.

Divalproex sodium is approved for the following uses:

• Seizure Disorders: Monotherapy and adjunctive therapy for complex partial seizures, and for simple and complex absence seizures in adults and pediatric patients 10 years and older. It is also used adjunctively in patients with multiple seizure types that include absence seizures.
• Bipolar Disorder: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features, in adults.
• Migraine Prophylaxis: Prevention of migraine headaches in adults. It is not indicated for acute migraine treatment.

Divalproex sodium

Divalproex sodium works by increasing the levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain. This stabilizes electrical activity in the brain, helping to prevent seizures and modulate mood swings in bipolar disorder. The drug’s effect on the nervous system helps reduce the frequency of migraine headaches, though the exact mechanism for migraine prevention is not fully detailed in the provided labeling.

General Dosage Guidelines

Divalproex sodium is taken orally. Doses are individualized based on condition, patient age, clinical response, and serum drug levels. The maximum recommended dose is generally 60 mg/kg/day.

For Seizure Disorders (Adults and Children ≥10 years)

• Monotherapy or Adjunctive Therapy for Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increase by 5 to 10 mg/kg/week as needed to control seizures.
• Simple and Complex Absence Seizures: Start at 15 mg/kg/day, titrate by 5 to 10 mg/kg/week until seizures are controlled or side effects limit increase.
• Doses over 250 mg/day should be divided.

For Bipolar Mania (Adults)

• Initial dosage typically 25 mg/kg/day, increase rapidly to achieve desired clinical response or plasma levels.
• Maximum dose 60 mg/kg/day.

For Migraine Prophylaxis (Adults)

• Start at 500 mg once daily for one week, then increase to 1,000 mg once daily.
• Doses up to 1,000 mg/day have been studied; dosage should be individualized.

Administration Notes

• Extended-release tablets must be swallowed whole, not crushed or chewed.
• Delayed-release capsules may be swallowed whole or opened and sprinkled on soft food (e.g., applesauce), but the mixture must be swallowed immediately without chewing.
• Plasma levels should be monitored if clinical response is inadequate or dose adjustments are needed.
• In patients converting from delayed-release to extended-release tablets, doses may need to be increased by 8-20%.

Special Populations

• Children under 2 years: Extreme caution advised due to high risk of fatal hepatotoxicity; only used as a sole agent if benefits outweigh risks.
• Elderly patients: Start at lower dose and titrate more slowly due to decreased clearance and increased sensitivity to sedation.

Monitoring

• Check serum drug levels to target 50-100 mcg/mL for seizure control, noting increased risks of thrombocytopenia at higher concentrations.
• Monitor platelet counts and coagulation tests due to bleeding risks.

• Patients with hepatic disease or significant hepatic dysfunction.
• Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG), such as Alpers-Huttenlocher Syndrome.
• Children under 2 years suspected of having POLG-related mitochondrial disorders.
• Known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid, including serious dermatologic reactions and angioedema.
• Patients with known urea cycle disorders.
• Use for migraine prophylaxis in women who are pregnant or women of childbearing potential not using effective contraception.

Boxed Warnings - Life-Threatening Risks

• Hepatotoxicity: Severe and sometimes fatal liver failure can occur, especially in the first 6 months. Risk is higher in children under 2 years, patients with mitochondrial disorders, and those on multiple anticonvulsants. Close monitoring with liver function tests is required.
• Fetal Risk: Valproate causes major birth defects, including neural tube defects, decreased IQ, and neurodevelopmental disorders. It is contraindicated in pregnancy for migraine prophylaxis and should only be used in pregnant women with epilepsy or bipolar disorder if no alternatives are effective. Effective contraception is required for women of childbearing potential.
• Pancreatitis: Life-threatening pancreatitis, sometimes hemorrhagic, can occur in children and adults. Symptoms such as abdominal pain, nausea, vomiting require urgent evaluation. If diagnosed, treatment should be discontinued.

Additional Warnings and Precautions

• Suicidal Thoughts and Behavior: Antiepileptic drugs including divalproex sodium may increase risk; monitoring is advised.
• Bleeding and Hematologic Effects: Thrombocytopenia and coagulopathy risk increases with higher plasma levels; platelet and coagulation monitoring is recommended.
• Hyperammonemia: May cause encephalopathy and lethargy; ammonia levels should be checked if symptoms occur, especially if used with topiramate.
• DRESS and Hypersensitivity Reactions: Serious dermatologic and multiorgan hypersensitivity reactions reported; discontinue if suspected.
• Hypothermia: Reported during therapy with or without hyperammonemia, especially with concomitant topiramate.

Common Side Effects

• Gastrointestinal irritation (may be reduced by taking with food or gradual dose increases)
• Somnolence (especially in elderly)
• Elevated liver enzymes
• Thrombocytopenia

Serious Side Effects

• Hepatotoxicity (sometimes fatal)
• Pancreatitis (including fatal hemorrhagic cases)
• Severe hypersensitivity reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
• Coagulation disorders
• Suicidal ideation and behavior

• Divalproex sodium affects blood levels of several anticonvulsants including clonazepam, diazepam, ethosuximide, lamotrigine, phenobarbital, carbamazepine, and phenytoin, requiring monitoring and possible dose adjustments.
• Valproate may alter metabolism of tolbutamide and other drugs.
• Concomitant use with topiramate increases risk of hyperammonemia and hypothermia.
• No dosage adjustment of carbamazepine or phenytoin was needed during adjunctive therapy in clinical studies, but monitoring plasma levels is advised.

Pregnancy

Divalproex sodium carries a high risk of major congenital malformations including neural tube defects, decreased IQ, and neurodevelopmental disorders in children exposed in utero. It is contraindicated for migraine prophylaxis in pregnant women and in women of childbearing potential without effective contraception. It should only be used during pregnancy for epilepsy or bipolar disorder if other treatments have failed or are not acceptable. Effective contraception is mandatory in women of childbearing age on this medication.

Lactation

The label does not provide specific recommendations regarding breastfeeding; consult healthcare provider for patient-specific advice.